Cassava Sciences Inc vs Western Union Co — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Western Union Co trades at $7.05 (market cap $2.19B). The key difference: Western Union Co is far larger — about 45.9× Cassava Sciences Inc's market cap, and Western Union Co pays a 13.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | WU | |
|---|---|---|
Market Cap | $47.75M | $2.19B |
Sector | Health | Technology |
52-Week High | $4.64 | $10.28 |
52-Week Low | $0.87 | $6.36 |
Enterprise Value | -$34.93M | $2.10B |
Dividend Yield | — | 13.37% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Western Union (WU) trades at $7.08, down 1.12% today, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Valuation ratios appear attractive with a P/E of 5.71 and P/S of 0.56, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company maintains a strong dividend yield, paying $0.24 quarterly, and recently launched Stablecard with Rain to expand digital services.
The outlook is cautious due to earnings volatility and competitive pressures in money transfers. Opportunities include cost management and digital growth, but risks from declining retail performance and high debt levels persist. Analyst consensus is mixed with a $7.14 price target, reflecting uncertainty over turnaround efforts.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →